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Abstract: OBJECTIVE: To assess the validity of the 6 min walk test (6MWT) in pulmonary arterial
hypertension secondary to systemic sclerosis (PAH-SSc) according to the OMERACT filter. METHODS:
A systematic literature search was conducted from 1966 through June 2009. The assessment of validation
of the 6MWT was based on the OMERACT filter criteria with the domains ’truth’, ’discrimination’
and ’feasibility’. RESULTS: From the 57 articles identified, 9 (16%) were analysed. The 6MWT had
face validity as it has been accepted by the registration agencies as a surrogate of PAH-SSc. It was
sensitive to change in response to therapy, with effect sizes ranging from 0.30 to 1.37 with a parallel
variation of haemodynamic parameters measured by right heart catheterisation. Feasibility was also
validated. Content validity was not confirmed as this test was not specific for PAH-SSc. There was some
evidence that 6MWT might meet criterion/construct validity, reproducibility and sensitivity to change
over time, but insufficient data were provided to fully validate these components. CONCLUSIONS:
Current evidence suggests partial validation of the 6MWT in PAH-SSc according to the OMERACT
filter. Further dedicated studies are needed to validate completely the 6MWT in PAH-SSc, taking into
account the comorbidities interfering with the 6MWT.
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ABSTRACT
Objective To assess the validity of the 6 min walk test 
(6MWT) in pulmonary arterial hypertension secondary to 
systemic sclerosis (PAH-SSc) according to the OMERACT 
fi lter.
Methods A systematic literature search was conducted 
from 1966 through June 2009. The assessment of 
validation of the 6MWT was based on the OMERACT 
fi lter criteria with the domains ‘truth’, ‘discrimination’ and 
‘feasibility’.
Results From the 57 articles identifi ed, 9 (16%) were 
analysed. The 6MWT had face validity as it has been 
accepted by the registration agencies as a surrogate 
of PAH-SSc. It was sensitive to change in response to 
therapy, with effect sizes ranging from 0.30 to 1.37 
with a parallel variation of haemodynamic parameters 
measured by right heart catheterisation. Feasibility was 
also validated. Content validity was not confi rmed as 
this test was not specifi c for PAH-SSc. There was some 
evidence that 6MWT might meet criterion/construct 
validity, reproducibility and sensitivity to change over 
time, but insuffi cient data were provided to fully validate 
these components.
Conclusions Current evidence suggests partial 
validation of the 6MWT in PAH-SSc according to the 
OMERACT fi lter. Further dedicated studies are needed to 
validate completely the 6MWT in PAH-SSc, taking into 
account the comorbidities interfering with the 6MWT.
INTRODUCTION
Pulmonary arterial hypertension (PAH) has emerged 
as one of the leading causes of death in systemic 
sclerosis (SSc).1 Despite therapeutic advances 
which improved the prognosis of this condition, 
outcome measures for PAH are poorly deﬁ ned and 
those available are only partially validated or con-
sidered as not optimal.2 Indeed, the evaluation of 
PAH is made difﬁ cult by other cardiopulmonary 
comorbidities associated with SSc (ie, intersti-
tial lung disease or primary myocardial involve-
ment). Recently, 78 experts in PAH-SSc from the 
OMERACT-EPOSS (Expert Panel on Outcome 
Measures in PAH related to SSc) Group deﬁ ned 
a core set of outcome measures using the Delphi 
consensus methods.3 Among these tools, the 6 min 
walk test (6MWT) is the most widely used as a pri-
mary outcome to assess therapeutic efﬁ cacy in PAH 
clinical trials and is accepted by the Food and Drug 
Administration. Although this outcome measure is 
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recommended by this expert group, it is necessary 
to ascertain if the 6MWT is validated in PAH-SSc 
since its aetiology and prognosis are not the same 
as idiopathic pulmonary arterial hypertension. The 
aim of this study was to analyse the status of vali-
dation of the 6MWT in SSc according to the crite-
ria of the OMERACT ﬁ lter.4 Different from other 
approaches performed several years ago, we used 
an evidence-based systematic literature analysis 
for this assessment and included recent primary 
research articles from 1966 through June 2009, 
taking into consideration the large number of pub-
lished articles in the ﬁ eld during recent years.
METHODS
Full details of the methodology are shown in the 
online data supplement.
Systematic literature review
Studies in which the 6MWT was used for the eval-
uation of patients with PAH/PH-SSc were searched 
in PubMed and the Cochrane Controlled Trial 
Register, as were relevant references from retrieved 
articles during the last 2 years. Inclusion and exclu-
sion criteria emphasised articles in which patients 
with SSc-PAH were predominant or could be anal-
ysed separately and required ≥5 patients.
Quality assessment
Evidence was assessed with respect to the level of 
the evidence and the quality of randomised con-
trolled trials (RCTs) was assessed according to the 
Jadad criteria.5 6 The quality criteria according to 
the deﬁ nition of pulmonary hypertension are sum-
marised in table 1.
Application of the OMERACT fi lter
The OMERACT process involves consensus on out-
come measures and is based on the ‘OMERACT ﬁ lter’ 
which is composed of three key components: truth 
(face, content and criterion/construct validity), discrim-
ination (reliability, sensitivity to change and discrimi-
nant capacity in response to therapy) and feasibility.4
RESULTS
Results of the systematic literature search
From the 57 articles identiﬁ ed, 9 were ﬁ nally 
included for further analysis (see ﬁ gure in online 
supplement).7–15
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Quality assessment of retrieved articles
Five studies were RCTs (level 1b),7 10 13–15 one was a longitudinal 
study with comparison to a historical control group (level 2b)12 and 
three were descriptive studies (level 3).8 9 11 The mean±SD Jadad 
score for RCTs was 4.1±1.0. Seven studies included well-deﬁ ned 
PAH-SSc subgroups according to quality level A17 9 10 12–15 and two 
studies were classiﬁ ed C18 11 (see table in online supplement).
Status of validation according to the OMERACT criteria for 
the 6MWT
Truth
Face validity
An agreement by a group of experts is required to deﬁ ne the 
appropriateness of 6MWT to be used for the evaluation of PAH 
(table 2). As it was accepted by the registration agencies of the 
USA and Europe as a surrogate of PAH and selected by the 
EPOSS Group as part of the core set of outcome measures for 
SSc, this test clearly has face validity.
Content validity
6MWT did not pass this speciﬁ c ﬁ lter as no paper evaluated 6MWT 
in a wide-ranging and comprehensive group of patients with SSc. 
Moreover, indirect evidence suggests that the 6MWT is not spe-
ciﬁ c for PAH-SSc-related exercise impairment. Thus, in three dif-
ferent studies, 6MWT was also associated in multivariate analysis 
with measures of myocardial involvement, interstitial lung disease, 
musculoskeletal disorders and inﬂ ammation.8 9 11 While there is no 
study available in SSc-PAH with the highest quality level A1, the 
expert group agreed that, based on the evidence from non-PAH 
studies, the 6MWT will very likely not meet this criterion and rated 
content validity as not validated.
Criterion validity/construct validity
Since the 6MWT was never tested against the external or ‘gold’ 
standard (right heart catheterisation (RHC)) in any study of 
patients with SSc-PAH, the 6MWT does not meet this aspect of 
validation. As an alternative, correlations with other validated 
parameters were searched to estimate concurrent and conver-
gent validity as surrogates for criterion validity and as indica-
tors of overall construct validity. One study found that 6MWT 
was signiﬁ cantly associated with mortality in univariate analy-
sis. Survival increased by 24% for every 100 m further a patient 
could walk (HR 0.76, 95% CI 0.58 to 0.98, p=0.037). However, 
this result was not conﬁ rmed in the multivariate analysis. In 
this study the 6MWT was not an independent risk factor for 
decreased survival in patients with PAH-SSc (HR 0.81, 95% CI 
0.59 to 1.12, p=0.20).12 At this time the 6MWT has therefore 
not met the test of criterion/construct validity, but it was rated 
partially validated for construct validity by the expert group as 
there is some evidence that it might correlate with survival.
Discrimination
Insufﬁ cient data were provided in the analysed studies to 
assess the reliability and reproducibility of the 6MWT in the 
speciﬁ c situation of PAH-SSc (κ coefﬁ cient and intraclass and 
interclass correlation coefﬁ cients were not assessed). However, 
because tests in SSc-ILD indicated reproducibility, it was rated 
partially validated.16 It was not possible to assess the sensi-
tivity to change over time because there were no suitable 
data to analyse. As an alternative, we assessed the sensitivity 
to change of the 6MWT in the placebo groups of ﬁ ve high-
quality RCTs.7 10 13–15 These studies provided data on exer-
cise capacity for 100 patients included in the placebo groups. 
Unfortunately, there were insufﬁ cient data to calculate the 
standardised response mean in all studies and thus complete a 
meta-analysis. However, it is noteworthy that, over time, there 
was a deterioration in the mean distance walked in this speciﬁ c 
group in four studies (deterioration from 2.6 m to 38 m) and 
no variation in one study (improvement of 3±8 m). Thus, with 
regard to these data, the 6MWT was rated by the experts as at 
least partially validated.
Discriminant capacity in response to therapy was validated in 
the ﬁ ve high-quality RCTs described above. These studies pro-
vided data on exercise capacity for 283 patients with SSc. The 
mean trial duration was 13±4.0 weeks. The 6MWT was sensitive 
to change in response to therapy with effect sizes ranging from 
0.30 to 1.37 (table 3). Moreover, there was also a parallel varia-
tion between the effect sizes of the 6MWT and the effect sizes 
of haemodynamic parameters (mean pulmonary artery pressure 
(mPAP) and pulmonary vascular resistance (PVR)) during treat-
ment, as measured by RHC in the analysed trials (table 3).
Feasibility
The 6MWT is easy to perform and values are easy to interpret 
with no special equipment required; minimal training is required 
Table 1 Quality assessment of studies according to the defi nition of 
pulmonary arterial hypertension and the exclusion of other forms of 
pulmonary hypertension
Defi nition of PAH
Pulmonary 
fi brosis and left 
heart disease 
excluded
Pulmonary 
fi brosis and left 
heart disease 
not excluded
RHC
 mPAP >25 mm Hg at rest and/or 
mPAP >30 mm Hg at exercise
A1 A2
Doppler echo
 PASP/TG ≥45 mm Hg B1 B2
Doppler echo
 35 mm Hg ≤ PASP/TG <45 mm Hg C1 C2
Other (or not defi ned) D1 D2
For detailed defi nition of quality criteria A–D and category 1/2, please refer to the 
Methods section and the online supplement. Only if A1 studies were available, specifi c 
OMERACT criteria of 6MWT were considered validated (V) or not valid (NV) (see legend 
to table 2 for detailed defi nitions).
6MWT, 6 min walk test; mPAP, mean pulmonary artery pressure; PAH, pulmonary 
arterial hypertension; PASP/TG, pulmonary arterial systolic pressure/tricuspid gradient; 
RHC, right heart catheterisation.
Table 2 Validation of 6MWT in PAH-SSc according to the OMERACT 
fi lter
OMERACT fi lter criterion Validation
Highest quality of 
PAH defi nition
Truth
 Face validity V NA
 Content validity NV C1
 Criterion validity ND No studies
 Construct validity PV A1
Discrimination
 Sensitivity to change over time PV A1 (placebo groups)
 Discrimination capacity in response to 
therapy
V A1
 Reliability (reproducibility) PV Studies in SSc-ILD
Feasibility V A1
V, valid: a criterion was judged validated if appropriate information was available from 
studies including exclusively patients with PAH-SSc (quality defi nition A1, see table 1 
for details). Exception is face validity, which is evaluated by the judgement of experts 
as an appropriate measure rather than by specifi c studies. NV, not valid: similarly, a 
criterion was judged not valid if appropriate information was available from studies 
including exclusively patients with PAH-SSc (quality defi nition A1, see table 1 for 
details). PV, partially validated: a criterion was judged partially validated if data from 
studies lower than quality level A1 indicated that the criterion is validated.
6MWT, 6 min walk test; NA, not applicable; ND, no data; PAH, pulmonary arterial 
hypertension; PAH-SSc, pulmonary arterial hypertension secondary to systemic sclerosis.
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and patient/physician acceptance is good. It is also an inexpen-
sive test that requires a minimum number of healthcare staff 
and can be performed in an ofﬁ ce setting.11 Thus, availability 
of the 6MWT at investigational sites and its practicality both in 
specialised and community practices make it an eminently fea-
sible test.17 As a limitation, there might be rare disease-related 
manifestations such as arthritis or severe skin ﬁ brosis where the 
test cannot be performed.
DISCUSSION
This is the ﬁ rst study to address the validity of 6MWT as an out-
come measure in PAH-SSc, with respect to the OMERACT ﬁ lter, 
using a systematic literature review. Current evidence suggests 
that the 6MWT passes the ﬁ lter for face validity, discriminant 
capacity with treatment and feasibility. However, content valid-
ity is not validated and no robust data allow full conﬁ rmation of 
construct/criterion validity, reliability and sensitivity to change 
over time (table 3).
The heterogeneity of the trials limited the analysis to only a 
few studies with patients with PAH-SSc diagnosed according 
to the highest quality level A1. Many studies included patients 
with pulmonary hypertension related to PAH, left heart dis-
ease and severe interstitial lung disease, without subgroup 
analysis which allowed one to examine SSc-PAH per se.
Content validity was considered by the expert group as not 
valid, although one study showed that impairment of exercise 
performance was associated with pulmonary hypertension.18 
However, this study had a low C2 quality level and was excluded 
from the initial analysis as exercise capacity was not assessed 
by the 6MWT. Moreover, recent data have shown that patients 
with SSc judged free of both cardiac and pulmonary diseases 
had reduced exercise capacity, suggesting that some SSc-speciﬁ c 
or non-speciﬁ c comorbidities independent of cardiopulmonary 
involvement, such as articular/soft tissue involvements, may 
inﬂ uence exercise capacity in SSc.8 19 20 This has an impact on 
future trial design in patients with SSc-PAH. If the 6MWT is 
chosen as an outcome, patients with signiﬁ cant comorbidities 
either need to be excluded or need to be controlled for by appro-
priate tests.
Despite insufﬁ cient data to assess the reliability and reproduc-
ibility of the 6MWT in PAH-SSc per se, follow-up analyses by 
Buch et al16 showed the high reproducibility of the 6MWT in 
patients with SSc-ILD. The within-subject intertest Pearson cor-
relation coefﬁ cient on repeated 6MWT was reported to be 0.95 
(p<0.001). Based on all of the above, reproducibility was rated 
by experts as partially validated.
We used placebo groups of RCTs to assess the sensitivity to 
change over time. One could argue that placebo is a form of 
Table 3 Validation of the discriminant capacity over treatment of the 6MWT
Author, year, 
reference
Quality 
(Jadad) SSc patients
Inclusion criteria for 
PAH Intervention Comparator Study duration
Effect size (95% CI) 
for 6MWT
Effect size (95% CI) 
for haemodynamic 
measures
Denton et al, 20067 5/5 N=52 (79%) CTD-related PAH
WHO III/IV
6MWT 150–500 m
mPAP >25 mm Hg, 
PVR >240
Bosentan 
62.5 mg ×2/day 
during 4 weeks then 
125×2 mg/day 
250 mg/day
Placebo 12–16 weeks 0.30 (−0.2 to 0.8) mPAP
No data
PVR
No data
Girgis et al, 200714 4/5 N=38 (46%) CTD-related PAH
WHO II, III and IV
6MWT >450 m 
excluded
mPAP >25 mm Hg 
at rest PVR ≥240
Sitaxsentan
50 mg/day
100 mg/day
300 mg/day
Placebo 12 weeks 0.57 (−0.2 to 1.3) mPAP
−0.9 (−1.67 to 0.1)
PVR
−1.1 (−1.9 to 0.3)
Badesch et al, 200715 5/5 N=38 (45%) CTD-related PAH
WHO II-IV
6MWT 100–450 m
mPAP ≥25 mm Hg
Sildenafi l
20 mg × 3/day
40 mg × 3/day
80 mg × 3/day
Placebo 12 weeks 0.65 (0.0 to 1.3)
0.68 (0.0 to 1.3)
0.31 (−0.2 to 1.0)
mPAP
−0.5 (−1.2 to 0.1)
−0.4 (0.9 to 0.2)
−0.4 (−1.0 to 0.2)
PVR
−0.5 (−1.1 to 0.1)
−0.3 (−0.9 to 0.3)
−0.3 (−0.9 to 0.3)
Badesch et al, 200013 3/5 N=110 (100%) SSc-related PAH
mPAP ≥35 mm Hg
PVR >240
Epoprostenol 
intravenously
Starting from 
2 ng/kg/min 
intravenously and 
increased based 
on symptoms and 
adverse events 
plus conventional 
therapy
Conventional 
therapy
12 weeks 1.2 (0.8 to 1.6) mPAP
−0.6 (−0.9 to −0.2)
PVR
−0.9 (−1.3 to −0.5)
Oudiz et al, 200410 3/5 N=45 (50%) SSc-related PAH
mPAP ≥25 mm Hg
PVR ≥3 Wood units
6MWT 50–450 m
Treprostinil 
intravenously
Starting from 1.25 
to 2.5 ng/kg/min 
and increases of 
1.25–2.5 ng/kg/min 
every 1–2 weeks. 
Target dose based 
on response to 
therapy and adverse 
effects and did not 
exceed 
22.5 ng/kg/min
Placebo 12 weeks 1.37 (0.9 to 1.9) mPAP
−1.0 (−1.4 to −0.6)
PVR
−2.3 (−2.8 to −1.8)
6MWT, 6 min walk test; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PVR, pulmonary vascular resistance; SSc, systemic sclerosis.
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intervention and may be a bias. This explains why experts rated 
this item as partially validated (table 2). However, it appears 
likely that the 6MWT also shows sensitivity to change with-
out placebo intervention. Although the 6MWT had discriminant 
capacity with treatment, this result has to be taken cautiously 
because most of the effect sizes calculated were not signiﬁ cant. 
This may have been related to the variability of the testing pro-
cedures or to the low number of patients with SSc included 
(only ﬁ ve trials allowed subgroup analyses of pivotal RCTs on 
approximately 20–25% of the total population). On the other 
hand, two high-quality RCTs, performed in a population of 
patients with PAH-SSc with sufﬁ cient power to detect a signiﬁ -
cant difference, clearly showed the sensitivity to change of the 
6MWT when the patients were treated with epoprostenol and 
treprostinil.13
This structured literature review and the assessment of identi-
ﬁ ed papers according to the OMERACT ﬁ lter revealed several 
aspects of 6MWT that need further validation in additional 
studies (criterion/construct validity, reliability and sensitivity 
to change over time). Although the OMERACT ﬁ lter is not an 
obligatory framework to assess the full validation of 6MWT as 
an outcome measure in PAH-SSc, it deﬁ nes a speciﬁ c research 
agenda which needs to be addressed.
Deﬁ nite validation of construct/criterion validity of the 6MWT 
requires signiﬁ cant correlation between the gold standard RHC 
and the 6MWT speciﬁ cally in PAH-SSc cross-sectional studies.
Validation of reliability of the 6MWT in PAH-SSc requires 
comparisons of repeated 6MWT assessments performed within 
a short time period by the same investigator (intraobserver vari-
ability) and by two independent investigators (interobserver vari-
ability) at the same time in patients with well-deﬁ ned PAH-SSc.
The type of studies required to assess the validity of 6MWT 
with respect to the sensitivity to change are longitudinal studies 
including patients with PAH-SSc without treatment and parallel 
6MWT and RHC evaluations at different time points.
Our study did not assess the 6MWT in patients with heart 
or lung disease in general. Further dedicated studies are thus 
needed to assess the 6MWT in patients with SSc with interstitial 
lung disease or primary myocardial involvement.
In conclusion, this systematic literature analysis showed that 
6MWT in PAH-SSc fulﬁ lls the OMERACT criteria only for face 
validity, discriminant capacity with treatment and feasibility. 
Content validity was considered as not valid. Further studies 
are therefore needed to completely validate the 6MWT in PAH-
SSc for construct/criterion validity, reliability and sensitivity to 
change.
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